A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Open Access
- 30 April 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (5), 619-625
- https://doi.org/10.1016/j.annonc.2020.01.074
Abstract
No abstract availableFunding Information
- Prostate Cancer UK
- Movember Foundation
- U.S. Department of Defense
- Prostate Cancer Foundation
- National Institute for Health Research
- Astellas Pharma
- European Society for Medical Oncology
- Cancer Research UK
This publication has 30 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer GrowthCancer Cell, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate CancerClinical Cancer Research, 2009
- Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma DevelopmentCancer Research, 2008
- Mitogenic signaling pathways induced by G protein‐coupled receptorsJournal of Cellular Physiology, 2007
- Integrating signals from RTKs to ERK/MAPKOncogene, 2007
- Negative regulation of the serine/threonine kinase B-Raf by AktOnline Journal of Public Health Informatics, 2000
- Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)Science, 1999